Euthymics is developing products for two central nervous system disorders of significant unmet medical need: Major Depressive Disorder (MDD) and Attention Deficit/Hyperactivity Disorder (ADHD). According to the Federal government MDD affects over 15 million American adults and ADHD affects nearly 10 million American adults.
Serotonin, norepinephrine, and dopamine are three important neurotransmitters found in the brain and are associated with mood, focus, cognition and pleasure.
We have proprietary technology enabling us to develop single-molecule monotherapies that act on all three neurotransmitters in specific ratios effective for each indication.
Euthymics’ lead compound, Amitifadine (formerly EB-1010), is being evaluated in TRIADE, an advanced phase 2b/3a clinical trial at 41 sites in the US, for patients with major depressive disorder (MDD) not responding to initial therapy with first line antidepressant therapy.
Our second compound, EB-1020, in a Phase 1 clinical trial, is being developed for adult ADHD, an under-diagnosed and under-treated disorder affecting nearly 10 million people in the US.
Euthymics Bioscience, located in Cambridge, Massachusetts, is a privately-held company founded in 2009.
Euthymics has been funded in a $28m series A venture capital investment by Novartis Venture Fund, Venture Investors, Hambrecht & Quist Capital Management and GBS Partners. Key members of the Euthymics leadership team are experienced drug developers and have been involved in several of the most successful neuroscience medications in our lead indications.